Graphic: corner
spacer
Graphic: corner
spacer spacer
nav left edge
nav right edge
spacer

Updated News Release to our U.S. customers 2/12/10:

OptiGen is reporting news regarding its legal claims against InGen, Rick Dobbins and other defendants whenever definitive progress has been made.  The following statement was approved jointly by OptiGen and Texas A&M.  OptiGen is committed to protecting its intellectual property and will report other significant developments as they happen.

Further details on this case have been summarized at http://ip.law360.com/articles/148596

JOINT STATEMENT

OptiGen, LLC (“OptiGen”) and Texas A&M University (“Texas A&M”) have resolved OptiGen’s patent infringement claims against Texas A&M related to its testing of canine DNA for certain genetic disorders.

In January and April 2009, OptiGen filed lawsuits arising out of the infringement of a number of patents to which OptiGen holds exclusive licenses.  The consolidated actions charged Texas A&M, among others, with infringement of patents related to the testing of Progressive Rod-Cone Degeneration (PRCD), CLAD (Canine Leukocyte Adhesion Deficiency), CSNB/prad (Congenital Stationary Night Blindness or Retinal Dystrophy), and FN (Autosomal Recessive Nephropathy).  Texas A&M did DNA testing for these disorders at the request of Richard Dobbins, the CEO of PinPoint DNA Technologies, Inc. and the General Manager of International Genetics, Inc. (also known as InGen).  Mr. Dobbins, PinPoint and InGen are defendants in OptiGen’s ongoing patent infringement lawsuits.

The testing of these genetic disorders are covered by the following patents to which OptiGen holds exclusive licenses:  U.S. Patent Nos. 5,804,388; 7,312,037; 7,285,388; 6,210,897; 6,201,114; and 6,428,958.

Texas A&M has agreed to a settlement with OptiGen.  Texas A&M has ceased any and all testing related to these patents and has agreed not to resume any such testing in the future.  Texas A&M regrets that its testing has caused confusion among the community of dog owners and breeders.

 

 

 

 

 

 

       

 

 

 

 

 

 

042290/00002 Litigation 7017812v2

 

 


spacer
Graphic: footer bar left
OptiGen®, LLC · Cornell Business & Technology Park · 767 Warren Road, Suite 300 · Ithaca, New York 14850
Tel: 607 257 0301 · Fax: 607 257 0353 · email: genetest@optigen.com or optigen@clarityconnect.com
Graphic: footer bar right
spacer spacer
spacer
spacer
spacer